Aspecto esperado: Solucin transparente, incolora, sin partculas
The orforglipron analysis looks at an oral GLP-1 agonist in development
In particular, the major histological changes in early DKD include tubular cell hypertrophy, thickening of the tubular basement membrane and interstitial inflammation with mononuclear cell infiltration
Following abrupt or tapered discontinuation in placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue
Contraindications are screened